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Abstract
Alport syndrome (AS) is a genetic disorder involving mutations in the genes encoding collagen IV α3, α4 or α5
chains, resulting in the impairment of glomerular basement membrane. Podocytes are responsible for production
and correct assembly of collagen IV isoforms; however, data on the phenotypic characteristics of human AS podo-
cytes and their functional alterations are currently limited. The evident loss of viable podocytes into the urine of
patients with active glomerular disease enables their isolation in a non-invasive way. Here we isolated, immortalized,
and subcloned podocytes from the urine of three different AS patients for molecular and functional characterization.
AS podocytes expressed a typical podocyte signature and showed a collagen IV profile reflecting each patient’s muta-
tion. Furthermore, RNA-sequencing analysis revealed 348 genes differentially expressed in AS podocytes compared
with control podocytes. Gene Ontology analysis underlined the enrichment in genes involved in cell motility,
adhesion, survival, and angiogenesis. In parallel, AS podocytes displayed reduced motility. Finally, a functional per-
meability assay, using a podocyte–glomerular endothelial cell co-culture system, was established and AS podocyte
co-cultures showed a significantly higher permeability of albumin compared to control podocyte co-cultures, in both
static and dynamic conditions under continuous perfusion. In conclusion, our data provide a molecular characteriza-
tion of immortalized AS podocytes, highlighting alterations in several biological processes related to extracellular
matrix remodelling. Moreover, we have established an in vitromodel to reproduce the altered podocyte permeability
observed in patients with AS.
© 2020 The Authors. The Journal of Pathology published by JohnWiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Alport syndrome (AS) is a genetic disorder that affects
one in every 50 000 newborns. Around 80% of AS fam-
ilies have X-linked inheritance caused by mutations in
the COL4A5 gene, while the others have autosomal
recessive, or less commonly autosomal dominant, dis-
ease, caused by mutations in COL4A3 or COL4A4 genes
[1]. These genes encode for three of the six different col-
lagen IV α-chains (α1–α6), which are assembled in type
IV collagen networks [2,3]. Collagen IV α3α4α5 hetero-
trimer is the main component of the basal membrane in
glomeruli, as well as in the cochlea, lens capsule, and ret-
ina [4,5]. Mutations in any one of the three genes lead to
the absence of the collagen IV α3α4α5 network, result-
ing in typical AS clinical features: kidney disease, hear-
ing loss, and eye abnormalities [1].
In particular, the absence of a correct collagen IV
α3α4α5 network impairs the functional properties of
the glomerular filtration barrier [6]. During nephronmat-
uration, podocytes express, assemble, and secrete colla-
gen IV α3α4α5 proteins that replace the initial
embryonic collagen IV α1α1α2 network in the glomeru-
lar basal membrane (GBM) [7]. After this developmen-
tal switch, the resulting mature GBM is a highly
organized 300–400 nm thick collagen IV network [8].
In AS patients, alterations of the GBM, presenting as
lamellation of the lamina densa, affect the function of
podocytes, which appear to be the first altered cell type.
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AS podocytes demonstrate foot process effacement,
resulting in impaired filtration of blood and passage of
blood and/or proteins into the urine [9,10]. Likewise,
in murine models of AS disease (Col4a3+/− and
Col4a3−/− mice), podocytes appear with specific mor-
phological alterations characterized by long filamentous
and round shaped projections as compared to the podo-
cytes of wild-type mice [11].
Since in glomeruli, the production of the collagen
IV α3α4α5 heterotrimer is restricted to podocytes
[12], their involvement in AS pathogenesis is of great
interest. Recently, the analysis of kidney biopsies of
AS patients clearly showed that podocyte loss starts
as early as birth and results in the progressive reduc-
tion of podocyte number per glomerulus with time,
correlating with overall renal damage [13]. In particu-
lar, podocyte number per glomerulus and podocyte
nuclear density are significantly reduced in AS
patients [14]. However, data on the phenotypic char-
acteristics of human AS podocytes and their func-
tional alterations are currently limited.
Several studies demonstrated that podocyte excretion
is a natural phenomenon which precedes proteinuria
[15,16] and that it might be a sensitive marker of glomer-
ular damage [16–19]. Importantly, this phenomenon
could also offer the possibility to isolate podocytes from
normal subjects and patients with glomerular disorders
[16]. Recently, podocytes isolated from the urine of AS
patients have been used for genetic characterization of
mutations [20]. However, the restricted cell doubling
of primary AS podocytes limits their use as an in vitro
model necessary for the characterization of their mor-
phological, molecular, and functional profile.
The goal of our study was to set up a novel human in
vitro model to evaluate possible functional and molecu-
lar alterations in human AS podocytes. Urine-derived
podocytes fromAS patients were isolated, immortalized,
and cloned, and their gene expression profile was char-
acterized by RNA sequencing, in comparison with nor-
mal urine-derived podocytes. Moreover, a three-
dimensional system of podocyte–glomerular endothelial
cell (GEC) co-culture was established to analyse the
selective filtration of AS podocytes, compared with con-
trol podocytes. Permeability was measured in both static
and dynamic co-culture conditions, confirming the
defective filtration observed in patients with AS.
Materials and methods
Patients
A total of three patients diagnosed with AS were
recruited in this study. All parents of the AS patients pro-
vided informed signed consent for urine collection and
subsequent experiments, and the Ethics Committee of
the University Hospital Leuven approved the research
protocol (S54695). The diagnosis was based on measur-
ing creatinine levels and estimated glomerular filtration
rate (eGFR) and was confirmed by the characterization
of the mutated Alport syndrome genes (Table 1). Patient
1 had decreased eGFR [chronic kidney disease (CKD)
stage 2], while patients 2 and 3 showed normal kidney
function. All patients had proteinuria and were treated
with enalapril. Patients 1 and 3 had perceptive hearing
loss; patient 2 had normal hearing. Urine-derived podo-
cytes were also isolated from a young healthy donor
(Table 1).
Generation of podocyte cell lines
Freshly collected urine was centrifuged at 200 × g for
10 min and the pellet was resuspended in DMEM/F-12
(Life Technologies, Carlsbad, CA, USA) supplemented
with 10% FCS (Invitrogen, Carlsbad, CA, USA),
50 IU/ml penicillin, 50 g/ml streptomycin, 5 mM gluta-
mine, 5 g/ml insulin, 5 g/ml transferrin, and 5 mg/ml
selenium (all from Sigma-Aldrich, St Louis, MO,
USA). Cells (AS and control podocytes) were immortal-
ized and subcloned using a temperature-sensitive Simian
virus 40 large T (SV40T) and human telomerase reverse
transcriptase vectors, as described previously [21]. AB
kidney-derived podocytes, immortalized using the same
protocol and kindly gifted by MA Saleem, were used as
an additional control [21].
Control and AS podocytes were grown at 33 C and
transferred to 37 C for 10–14 days to obtain fully dif-
ferentiated podocytes. Details are provided in





















AS 2 11 F COL4A5 Heterozygote p.(Gly926Alafs*70)
c.2777del
0.6 135 Enalapril
AS 3 22 M COL4A5 Hemizygote p.Gly849Glu (c.2546G>A) 0.36 122 Enalapril
Control 11 F – – – Neg – –
eGFR: estimated glomerular filtration rate.
Normal protein/creatinine ratio: 0.2 g/g; normal eGFR: ≥ 90 ml/min per 1.73 m2; control: healthy urine donor.
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supplementary material, Supplementary materials and
methods.
Purification of glomerular endothelial cells (GECs)
Primary normal glomerular microvascular endothelial
cells were previously obtained from cell outgrowths of
human glomeruli and CD31 sorting, and characterized
by morphology and expression of a panel of endothelial
antigens [22] (see supplementary material, Supplemen-
tary materials and methods and Figure S1).
RNA extraction and RT-qPCR
RNA was extracted using Trizol (Life Technologies)
according to the manufacturer’s protocol. Aliquots of
total RNA (200 ng) were reverse-transcribed using a
High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). Levels
of mRNA were assessed by qPCR, using a mix contain-
ing 5 ng of cDNA, 100 nM of each primer (see supple-
mentary material, Supplementary materials and
methods), and 1× SYBR Green PCR Master Mix
(Applied Biosystems), and assembled into a 96-well Ste-
pOne Real Time System (Applied Biosystems). Nega-
tive cDNA controls were cycled in parallel in each run.
Data are shown as relative quantification (2−ΔΔCt).
GAPDH expression was used to normalize cDNA
inputs. Sample similarity plots were generated using
Morpheus (https://software.broadinstitute.org/
morpheus/).
Protein extraction and western blotting
Cell pellets were lysed at 4 C for 15 min in RIPA buffer
(Sigma) supplemented with protease and phosphatase
inhibitors. Details are provided in supplementary mate-
rial, Supplementary materials and methods.
ELISA assays
The concentrations of human VEGFA, Col4α3, and
Col4α5 in protein lysate and supernatant of differenti-
ated podocytes were measured using ELISA kits accord-
ing to the manufacturer’s instructions (n = 3
experiments in duplicate). Details may be found in sup-
plementary material, Supplementary materials and
methods.
RNA sequencing and analysis
Details are presented in supplementary material, Supple-
mentary materials and methods. RNA-seq data have
been deposited in the GEO database (http://www.ncbi.
nlm.nih.gov/projects/geo/) under the GEO accession
number GSE134011.
Single-cell tracking assay
For each condition, 2000 differentiated cells per well
were seeded in a polystyrene, transparent 96-well plate,
6 h prior to the assay, in triplicate, as described
previously [23]. For 12 h, each well was imaged every
5 min at the same coordinates using 10× magnification.
Live imaging was performed on a Zeiss LSM 880 Airys-
canmicroscope (Carl ZeissMicroscopy GmbH, Oberko-
chen, Germany). Microscopy images were further
processed and analysed using Zeiss ZEN imaging soft-
ware (Carl Zeiss, Jena, Germany) and Fiji/ImageJ free
software. In brief, ten cells were tracked per well, yield-
ing 30 tracked cells per cell line. The total distance trav-
elled and the speed of the individual cells were recorded.
Immunofluorescence
Immunostaining was performed on cells co-cultured for
48 h on an insert, fixed in 4% paraformaldehyde. Imag-
ing was performed using a Leica TCS SP5 confocal sys-
tem (Leica Microsystems S.r.l., Wetzlar, Germany).
Details are provided in supplementary material, Supple-
mentary materials and methods.
Three-dimensional co-culture assembly
For all co-culture experiments, GECs were seeded first
on the lower PET membrane side at a density of
8 × 104 cells per 12-well insert (static co-culture: 3 μm
pore size, Falcon-Corning, Glendale, AZ, USA;
dynamic co-culture: 0.45 μm pore size, ipCELLCUL-
TURETM Track Etched Membrane, it4ip S.A., Lou-
vain-la-Neuve, Belgium) and, after 6 h, podocytes
were seeded on the upper side at the same density. Each
cell type was cultured in its growth medium for 48 h
before the permeability assay and mediumwere changed
once the day after cell plating.
Millifluidic system
For dynamic experiments, we used a millifluidic device,
fabricated by IVTech Srl (Lucca, Italy), consisting of
two independent circuits that work in parallel. During
permeability tests, the medium was maintained with a
flow rate of 100 μl/min and cells in the chamber were
subjected to a shear stress of 8 × 10−5 dyn/cm2. To
roughly calculate this value, the following equation
was used: τ = 6μQ/bh2, where μ is the medium viscosity
(g/cm per s), Q is the volumetric flow rate (cm3/s), b is
the channel width, and h is the channel height [24–26].
Permeability assays
Permeability assays were performed after 48 h of co-cul-
ture by measuring BSA filtration. Complete medium (1
ml) containing or not FITC-BSA (1 mg/ml, Sigma)
was placed in the lower endothelial and upper podocyte
compartments, respectively. To measure the podocyte
filtration ability in basal to apical direction, 100 μl of
medium was taken after 6 h from the podocyte compart-
ment and the passage of FITC-BSA was determined by
fluorimetry in triplicate. For the dynamic system, podo-
cyte medium enriched with FITC-BSA (1 mg/ml) was
circulated into the endothelial compartment, while nor-
mal culture medium circulated into the upper
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compartment. After 3 h of perfusion, the passage of
BSA-FITC across the barrier was determined by sam-
pling of fluid from the upper channel. FITC signal was
measured in triplicates using a fluorimeter.
Statistics
Data are shown as mean ± SD. At least three repli-
cates were performed for each experiment. Two-tailed
Student’s t-tests were used for analysis when two
groups of data were compared, while two-way
ANOVA with Dunnett’s multiple comparison test
was applied when comparing more than two groups
of data. All statistical analyses were performed using
GraphPad Prism software version 6.0 (GraphPad Soft-
ware, Inc, San Diego, CA, USA). p < 0.05 was con-
sidered significant.
Results
Generation of conditionally immortalized podocyte
lines from urine of patients with AS
We generated conditionally immortalized podocytes
from the urine of three different patients with AS (aged
16.5 ± 5.5 years) and from a normal subject (aged
11 years). AS patient 1 showed compound heterozygous
mutations in the COL4A3 gene, while AS patients 2 and
3 had mutations in the COL4A5 gene in heterozygosity
and in hemizygosity, respectively (Table 1). All AS
patients were characterized by an altered protein/creati-
nine ratio (0.48 ± 0.12 g/g), but only patient 1 presented
a mildly reduced eGFR (Table 1).
Primary urine-derived podocytes were immortalized
by inducing the expression of temperature-sensitive
SV40T and telomerase reverse transcriptase allowing
growth at 33 C and differentiation at 37 C [21]. Nine
clones were picked for each patient and were subse-
quently grown as separate cell lines. Conditionally
immortalized podocytes previously obtained from a nor-
mal renal biopsy and characterized [21] were used as an
additional control. At the permissive temperature of
33 C, AS podocytes proliferate in a comparable way
to normal urine-derived and kidney-derived podocytes,
used as controls (Figure 1A). After 10–14 days at
37 C, differentiated cells showed an irregular and
enlarged cell body with formation of protrusions very
similar to controls (Figure 1A).
Podocyte marker expression in differentiated AS
podocytes
To confirm the podocyte feature of AS podocytes, three
clones for each AS patient were analysed for the expres-
sion of the specific podocyte markers synaptopodin,
podocalyxin, nephrin, podocin, WT1, and VEGFA. All
markers were expressed by AS podocytes, although a
reduction in some adhesion molecules in relation to uri-
nary and tissue control podocytes was observed, in line
with previous reports [27]. In particular, levels of
nephrin and podocin were reduced in AS podocytes
compared with controls (Figure 1B), while synaptopo-
din showed only a trend for reduction. No differences
were observed in WT1 expression. Increased expression
of VEGFA was also found in AS patients 2 and 3 (Fig-
ure 1C). VEGFA transcript levels were also significantly
increased in AS patient 2 compared with controls. AS
podocytes also expressed lower levels of SYNPO
mRNA, but not of PODXL (Figure 1D). Glomerular
endothelial cells were used as a negative control (Fig-
ure 1D). The expression of podocyte markers in AS
podocytes was significantly increased after 10–14 days
of differentiation at 37 C, in relation to proliferating
cells at 33 C (Figure 1E), as reported for control kid-
ney-derived podocytes [21].
Taken together, these results indicate that AS podo-
cytes express most of the typical podocyte markers, with
a specific reduction of glomerular slit diaphragm
proteins.
Collagen IV isoform expression in differentiated AS
podocytes
In order to better evaluate the collagen IV characteris-
tics in the three different AS patients of our study, we
created 3D models of the protein secondary structure
of the C-terminal C4 domains, the terminal portion
predictable by 3D modelling (see supplementary
material, Supplementary materials and methods). The
models of Col4α3 and Col4α5 represent the normal
3D aspect of the protein C4 terminal domains. AS
patient 1 presented frameshift mutations in COL4A3
leading to a truncated amino-acid sequence at residues
690 (maternal allele) and 1613 (paternal allele), result-
ing in alterations of the conformation of C-terminal
C4 residues as shown in Figure 2A. Similarly, frame-
shift mutation of COL4A5 in AS patient 2 resulted in
a truncated amino-acid sequence at residue 994, caus-
ing the protein to be truncated and unfolded (Fig-
ure 2A) from one of the two X chromosomes. In
AS patient 3, a single nucleotide variant of COL4A5
was present, leading to minor differences from the
reference sequence, as shown in Figure 2A.
We subsequently analysed the expression of collagen
IV isoforms in three clones for each patient. At protein
level,COL4A3 gene-mutated podocytes fromAS patient
1 showed a significant reduction of COL4α3 protein in
both the cell lysate and the supernatant compared with
control (Figure 2B). In addition, COL4α5 protein was
also reduced (Figure 2B). In parallel, podocytes from
AS patients 2 and 3, mutated in the COL4A5 gene,
showed a significant reduction of Col4α5 protein com-
pared with control both in cell lysates and in the superna-
tant (Figure 2C). A reduction in Col4α5 protein was
confirmed in AS patient 3 by confocal microscopy (see
supplementary material, Figure S2). COL4a3 protein
was also reduced in the cell lysate, but not in the super-
natant (Figure 2C), of AS patients 2 and 3, as confirmed
at mRNA level in AS patient 2 (see supplementary mate-
rial, Figure S3).
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COL4A1 and COL4A2 transcript levels appeared sig-
nificantly increased in AS patient 1 compared with con-
trol podocytes (Figure 2D). These analyses confirm the
alterations in collagen IV expression by AS podocyte
lines, reflecting disease mutations.
RNA-sequencing analysis of differentiated AS
podocytes
RNA sequencing was performed on podocytes isolated
from urine of the three AS patients to investigate the
characteristics of the AS transcriptome, using urine-
Figure 1.Morphology and marker expression of cultured AS podocytes. (A) Representative light microscopy images of undifferentiated (upper
panels) and differentiated (lower panels) podocytes from normal urine (U-pod), normal kidney (K-pod), and AS patient urine. Original mag-
nification:×20; scale bar: 20 μm. (B) Western blot analysis (representative images and quantification) of nephrin, podocin, synaptopodin, and
WT1 of differentiated control (U-pod and K-pod) and AS podocytes. Data are expressed as mean ± SD of band intensity normalized to vinculin
or GAPDH of three different experiments. *p < 0.05. (C) VEGFA ELISA performed on cell lysates and cell supernatants obtained from differ-
entiated AS podocytes, compared with control (K-pod). Data are mean ± SD of three different experiments. *p < 0.05. (D) RT-qPCR for synap-
topodin (SYNPO), podocalyxin (PODXL), and VEGFA transcripts. Data are shown as relative quantification, normalized to GAPDH and to control
podocytes (U-pod). Three clones for each AS patient were used and data are expressed as mean ± SD of three different experiments. GECs
were used as a negative control. *p < 0.05 AS patient podocytes versus U-pod; #p < 0.05 AS patient podocytes versus kidney-derived podo-
cytes (K-pod); $p < 0.05 and $$$p < 0.0001 AS patient podocytes versus GECs (negative control). (E) RT-qPCR for podocyte marker transcripts
(SYNPO, PODXL, VEGFA) and collagen IV isoforms (COL4A3, COL4A5) of AS patient 1 podocytes before and after differentiation. Data shown as
relative quantification, normalized to GAPDH and to undifferentiated AS patient 1 podocytes, expressed as mean ± SD. ***p < 0.0001.
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derived podocytes as a control. A specific signature
composed of 68 podocyte-typical genes, previously
described by Lu et al [28], was investigated. AS podo-
cyte lines did not reveal significant differences from
the control (Figure 3A,B), confirming the podocyte phe-
notype of all AS cell lines (three clones per patient).
To identify altered gene expression profiles specific
for AS podocytes, we analysed the differential expres-
sion analysis of the three different AS podocyte lines
(three clones per patient) with respect to control podo-
cytes and detected a total of 348 deregulated genes (|
log2 fold-change| ≥ 0.8, adjusted p ≤ 0.1) out of 17 948
Figure 2. Collagen IV isoform expression in AS podocytes. (A) 3D models of the C-terminal C4 domains for Col4α3 and Col4α5 in AS patients
were generated using Phyre2 software, as described in supplementary material, Supplementary materials and methods. Images show the
structural modifications of COL4α3 and COL4α5 chains predicted on the basis of the different mutations, compared with normal. In patients
AS1 and AS2, frameshift mutations cause the protein to be truncated and with predicted alteration in folding (c.1937dup and c.2777del), or
conformation (c.4803del). In patient AS3, a single nucleotide variant (c.2546G>A) leads to minor differences in protein folding. (B) COL4α3
ELISA performed on cell lysates and cell supernatants of differentiated AS podocytes and control kidney-derived podocytes (K-pod). (C)
COL4α5 ELISA performed on cell lysates and cell supernatants of differentiated AS podocytes compared with control kidney-derived podo-
cytes (K-pod). ELISA data are expressed as arbitrary units (A.U.) and are the mean ± SD of three different experiments normalized to control
(referred to as 1). *p < 0.05; **p < 0.001; ***p < 0.0001. (D) RT-qPCR for COL4A1 and COL4A2 genes. Data are shown as relative quantifica-
tion, normalized to GAPDH and to control kidney-derived podocytes (K-pod). Three clones for each AS patient were analysed and data are
expressed as mean ± SD. GECs were used as a negative control. $p < 0.05 and $$$p < 0.0001 versus K-pod; *p < 0.05 versus U-pod.
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(Figure 3C). Specifically, 295 genes were up-regulated,
while 53 were down-regulated. To functionally charac-
terize the differentially expressed genes, Gene Ontology
(GO) enrichment analysis was performed. GO enrich-
ment analysis of biological processes highlighted the
presence of genes involved in morphogenesis and devel-
opment of a branching epithelium, extracellular matrix
and structure organization, cell adhesion, and cellular
response to endogenous stimulus (Table 2). Moreover,
the GO cellular components confirmed the role of extra-
cellular matrix and adhesion components (Table 2).
Using Ingenuity Pathways Analysis (IPA), we observed
a high level of connectivity among a large subset of dif-
ferentially expressed genes in AS podocytes (supple-
mentary material, Figure S4). The differential
expression, identified by RNA sequencing, of collagen
molecules (COL6A1, COL6A2, COL8A1), MMP2,
extracellular matrix–actin interactors (LAMA5, TALIN2,
RHOD), and adhesion molecules (SEMA5A, SEMA6A)
was confirmed by RT-qPCR analysis (Figure 4A).
Moreover, players of the WNT signalling pathway
(WNT2B, WNT10A) and molecules involved in cell
Figure 3. RNA-seq analysis of AS patients. (A) Heatmap of podocyte signatures showing similar levels of expression of podocyte genes in AS
podocytes (three clones per patient) and in control podocytes (U-pod). (B) Pearson similarity plot of podocyte signature showing similar levels
of expression of podocyte genes in AS podocytes (three clones per patient) and in control podocytes (U-pod). (C) Pie chart representation of
up-regulated (red) and down-regulated (blue) differentially expressed transcripts in AS patient- compared with control urine-derived podo-
cytes. RNA-seq was performed on three AS patients (AS P1, P2, P3), including three clones for each patient, and urine-derived podocytes (U-
pod) as a control.
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survival (IGFBP5, NGFR) and angiogenesis (THBS1,
SERPINE1) were also confirmed as differentially
expressed in AS podocytes by RT-qPCR (Figure 4A).
Taken together, these data highlight differential
expression in AS podocytes of genes involved in cell
adhesion, motility, and survival, with alteration in extra-
cellular matrix and cell junction component biosynthe-
sis, including collagen molecules. We therefore
analysed the possible impact of the altered podocyte
phenotype on their ability to migrate. As shown in Fig-
ure 4B,C, AS podocytes showed reduced motility in
terms of speed and distance with respect to controls.
Static permeability analysis of GEC–podocyte co-
cultures
To study the functionality of AS podocytes in vitro, a co-
culture system that mimics the interaction between
GECs and podocytes was assembled. GECs were seeded
on the bottom side of PET inserts, and differentiated kid-
ney-derived or AS podocytes were seeded on the upper
side (Figure 5A). The co-culture obtained consisted of
two homogeneous confluent layers of cells separated
by a porous PET membrane, as shown by immunofluo-
rescence (Figure 5B,C). The orthogonal view of co-cul-
ture slides shows a single thick layer of differentiated
podocytes with typical protrusions, separated by the thin
membrane from a single flat layer of GECs (Figure 5B).
The 3D reconstruction allowed the inspection, in all
three dimensions, of the co-culture assembly (Figure 5C
and supplementary material, Video S1).
A filtration assay was performed by measuring the
transit of FITC-BSA from the lower GEC compartment
to the upper podocyte compartment in different experi-
mental conditions (Figure 5D,E). Albumin permeability
was significantly reduced when GECs or/and control
podocytes were plated on the insert after 6 h of incuba-
tion (p < 0.0001). In particular, podocytes alone showed
a higher resistance to albumin transit through the mem-
brane than GECs alone. Interestingly, the presence of
AS podocytes alone significantly increased albumin per-
meability after 6 h, compared with control podocytes
alone (p < 0.0001). Finally, the same significantly
increased permeability was obtained when GEC–AS
podocyte co-cultures were compared with GEC–control
podocyte co-cultures (p < 0.0001), reproducing the
defective permeability typical in AS patients. Cell
counts of the plated cells showed no significant differ-
ence between control and AS podocytes, excluding that
the altered filtration of AS podocytes was due to an
increased cell detachment.
Dynamic permeability analysis of GEC–podocyte co-
cultures
To analyse the permeability of AS podocytes in dynamic
conditions, we adopted a millifluidic system that allows
continuous perfusion in co-culture under 8 × 10−5dyn/
cm2 shear stress (Figure 6A). Cells plated on the PET
membrane were maintained in the bioreactor for 48 h
before starting the permeability assay (Figure 6B). The
albumin filtration rate 3 h after GEC–AS podocyte co-
culture was significantly higher than that in the GEC–
control kidney-derived podocyte co-culture (Figure 6C,
p = 0.0012), confirming the increased permeability in
AS conditions. The permeability assays were therefore
able to recapitulate the AS alterations and confirm from
a functional point of view the altered podocyte pheno-
type demonstrated by molecular analysis.
Table 2. Gene Ontology (GO) analysis of differentially expressed genes.
GO biological process ID Name P value
1 GO:0060429 Epithelium development 3.618E-9
2 GO:0035295 Tube development 1.375E-8
3 GO:0061138 Morphogenesis of a branching epithelium 2.574E-8
4 GO:0002009 Morphogenesis of an epithelium 2.688E-8
5 GO:0007155 Cell adhesion 2.980E-8
6 GO:2000026 Regulation of multicellular organismal development 3.537E-8
7 GO:0030198 Extracellular matrix organization 3.907E-8
8 GO:0022610 Biological adhesion 3.931E-8
9 GO:0071495 Cellular response to endogenous stimulus 4.120E-8
10 GO:0043062 Extracellular structure organization 4.122E-8
GO cellular component ID Name P value
1 GO:0031012 Extracellular matrix organization 1.062E-8
2 GO:0070161 Anchoring junction 1.614E-5
3 GO:0045178 Basal part of cell 1.905E-5
4 GO:0005912 Adherens junction 2.586E-5
5 GO:0030054 Cell junction 1.335E-4
6 GO:0005604 Basement membrane 1.600E-4
7 GO:0044420 Extracellular matrix component 2.458E-4
8 GO:0005615 Extracellular space 1.487E-4
9 GO:0005925 Focal adhesion 3.051E-4
10 GO:0005815 Microtubule organization centre 3.052E-4
This table (in two parts) shows the Gene Ontology (GO) analysis of differentially expressed genes in AS patients compared with control urine-derived podocytes: biological
process and cellular component. In each table, the identification (ID) number, the name, and the P value associated with the GO are given.
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Discussion
Increasing evidence indicates that AS podocytes possess
an altered phenotype, beyond their altered collagen IV
synthesis, which can be involved in the pathogenesis
and progression of the disease. In the present study, we
isolated and characterized podocytes derived from the
urine of three patients with AS, with genetic alterations
of either COL4A3 or COL4A5, to assess common patho-
logical features due to collagen IV mutations. AS
podocytes showed specific changes in the transcript
levels of genes involved in cell motility, adhesion, pro-
liferation, and angiogenesis, with related alterations in
their functional properties. In order to study their perme-
ability in vitro, we set up a co-culture system that repro-
duced the functional aberrations typical of AS.
The availability of human AS podocytes in culture is
at present limited. Podocyte-like cells have been recently
obtained from induced pluripotent stem cells (iPS) of AS
patients [29,30] and may represent a promising
Figure 4. Validation of differentially expressed genes in AS. (A) mRNA expression of genes differentially expressed in AS related to cell motil-
ity, survival, and angiogenesis was evaluated by RT-qPCR. Data are shown as relative quantification, normalized to GAPDH and to control
kidney-derived podocytes (K-pod). One clone for each AS patient was analysed and the results are expressed as mean ± SD of the three
AS patients. (B) Single-cell tracking assay showing reduced motility in AS podocytes compared with urine-derived podocytes (U-pod) and
kidney-derived podocytes (K-pod). Three independent experiments were performed. *p < 0.05; **p < 0.001. (C) Representative images of
the cell motility of control podocytes and AS podocytes.
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approach. However, it might be difficult to obtain a pure
population for podocyte characterization, as differenti-
ated iPS cultures contained only 30–50% cells with
podocyte-like morphology [29]. Human urine, both
from patients and from healthy subjects, has been used
previously as a non-invasive valuable source of podo-
cytes [16]. In patients with active glomerular disease,
podocytes are shed from the glomerulus as a response
to local environmental factors. Urine-derived podocytes
from both patient and healthy subjects appear positive
for podocyte markers, viable, and able to grow in culture
[16]. For instance, urine-derived AS podocytes have
been recently obtained and used for genetic studies
[20]. In the present study, by exploiting the accelerated
podocyte loss in patients with AS [13,14], we success-
fully isolated AS podocytes from the urine of three
young patients with different collagen IV mutations;
conditionally immortalized the primary cells; and gener-
ated clonal lines in order to avoid the presence of con-
taminating non-podocytic cell types [16]. A similar
Figure 5. Static permeability assay in podocyte–GEC co-cultures. (A) Schematic representation of co-culture and experimental set-up: podo-
cytes and GECs were co-cultured for 48 h before the permeability assay was performed, as described in the Materials and methods section. (B)
Immunofluorescence of co-cultures showing the entire field and cross-sections (XZ and YZ) of both the upper podocyte layer (left) and the
lower GEC layer (right). Cells were stained with phalloidin (green) and nuclear staining was performed with Hoechst dye 33342. Original mag-
nification: ×400. (C) Snapshot of a perspective view of 3D reconstruction of the co-culture system (see supplementary material, Video S1). (D,
E) FITC-BSA permeability indicating albumin passage from the GEC compartment to the podocyte compartment was measured over 6 h. AS
podocytes alone or in co-culture showed significantly increased filtration compared with control podocytes alone or in co-culture. Data are
expressed as the mean amount of filtered BSA-FITC of four different experiments using at least three inserts for each condition in each exper-
iment. ***p < 0.0001 insert versus all conditions; $$$p < 0.0001 AS podocytes versus K-pod; ###p < 0.0001 AS podocyte co-culture versus K-
pod co-culture. U-pod: urine-derived podocytes; K-pod: kidney-derived podocytes; AS 1-2-3 pod: AS 1-2-3 patient podocytes.
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procedure has been described for urine-derived podo-
cytes from patients with focal and segmental glomerulo-
sclerosis [27].
The evaluation of a podocyte signature, using a panel
of 68 previously described genes [28], demonstrated the
podocyte nature of our clonal cell lines. Interestingly, we
found down-regulation of nephrin, podocin, and synap-
topodin in AS podocytes, confirming an observation
already described in AS kidney biopsies [31]. The rele-
vance of nephrin and synaptopodin levels was previ-
ously underlined by their negative correlation with the
degree of proteinuria in AS patients [31]. Moreover,
we confirmed in each AS podocyte line the alterations
in the expression of the mutated collagen IV isoform,
confirming that these AS lines are useful for investigat-
ing the defective collagen IV protein network and the
related podocyte alterations.
Literature data describing the AS podocyte phenotype
are quite scarce. Reduced podocyte number per glomer-
ulus and podocyte nuclear density [14] are commonly
described in human AS biopsies; however, podocyte
hypertrophy is the only cell feature reported [32]. In a
murine model of AS, electron microscopy analysis
showed the presence of altered podocyte cell bodies with
disorganized primary processes and protrusions [11,33].
From a molecular point of view, the glomerular gene
expression profile in a mouse model of AS highlighted
induction of MMP-10 and of the matrix protein mindin,
suggesting the involvement of matrix factors in progres-
sion [34]. Our study provides evidence of an altered phe-
notype of AS podocytes, in comparison with control
podocytes, common to the three different collagen IV
mutations, reflected into altered functions, namely
decrease in cell motility and increase in permeability.
By gene profiling, we identified restricted and specific
alteration of pathways related to basal membrane adhe-
sion, cytoskeleton modulation, and angiogenesis. These
data clearly indicate that AS podocytes display altered
features related to their interaction with the matrix. We
identified 295 up-regulated and 53 down-regulated
genes as compared to control urine-derived podocytes.
Among differentially expressed genes, we found
MMP2, whose altered expression was previously
described in an AS canine model [35], and LAMA5,
whose mRNA and protein up-regulation were shown in
AS-mouse glomeruli [36]. Among the identified genes
and pathways differentially expressed in AS podocytes,
dysregulated activation of the WNT pathway has been
Figure 6.Millifluidic system and permeability assay in podocyte–GEC co-cultures. (A) Schematic representation of the millifluidic system, as
described in the Materials and methods section. Cells seeded in the LiveBox (LB) were perfused with fluids circulated by peristaltic pumps at
100 μl/min in two independent circuits. (B) Representative image of a chamber of LiveBox. (C) After 48 h of podocyte/GEC co-culture, the
passage of FITC-BSA from the lower to the upper compartment was measured in the dynamic system over 3 h. The permeability in AS co-
cultures was significantly higher than that in control kidney-derived co-cultures. Data are expressed as mean ± SD of three different exper-
iments performed in parallel in control and AS podocytes. *p < 0.05. K-pod: kidney-derived podocytes.
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related to podocytopathies and proteinuria [37,38],
while IGFBP5 has been described as a promoter of epi-
thelial and fibroblast responses in fibrosis [39].
Taken together, the data indicate a general alteration
in AS podocytes of matrix interaction and cytoskeletal
organization, both necessary to prevent podocyte efface-
ment and maintain permeability control. For instance,
reduction of synaptopodin, which in turn controls RhoA
activity [40], as well as of cytoskeletal proteins such as
vinculin, known to maintain an intact glomerular filtra-
tion barrier [41], may induce impairment of cell motility
and increase permeability. Further investigation of small
GTPase activities in urinary AS podocyte would be
important to support the findings.
The observed alterations were reflected by altered
podocyte functions, mainly related to cell motility and
adhesion. Furthermore, we could reproduce the in vivo
AS permeability alteration by assembling a co-culture
system of AS podocytes and GECs. In our co-culture
model, we preferred to avoid the addition of an exoge-
nous collagen IV coating, as this GBM component is
defective in AS [42]. In this system, we measured the
passage of BSA-FITC from the lower (GEC compart-
ment) to the upper (podocyte compartment) side, which
is driven by osmotic forces and is halted by the presence
of cellular elements [42,43]. Similar to the defective glo-
merular permeability in AS patients [1], AS podocyte–
GEC co-cultures showed significantly increased filtra-
tion of albumin compared with the control co-cultures.
To mimic the physiological haemodynamic component,
we switched from a static to a dynamic model using a
millifluidic device. Also in this dynamic system the per-
meability in AS podocyte–GEC co-culture was signifi-
cantly increased. We are, however, aware that this
model does not fully mimic the glomerular alterations
observed in AS patients, due to the lack of a glomerular
basal membrane. Moreover, the isolation of urinary AS
podocytes detached by the glomerular basal membrane
in a disease state may introduce a selection bias.
In conclusion, we describe here a new human in vitro
model that molecularly and functionally reproduces the
defective AS podocytes. Using urine-derived AS podo-
cyte cell lines, we characterized molecular and morpho-
logical defects common to collagen IV mutation and
related to cell adhesion, motility, survival, and angiogen-
esis. Moreover, altered permeability measured in AS
podocyte–GEC co-culture underlines the potentiality of
this model. In fact, this in vitromodel could also be used
for the screening of pharmacological compounds, which
might restore functional properties to AS podocytes.
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